

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**HARBOUR**  
**BIOMED**  
**和 鉑 醫 藥 控 股 有 限 公 司**  
**HBM Holdings Limited**  
*(incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 02142)**

**INSIDE INFORMATION**  
**FURTHER UPDATE ON COLLABORATION**  
**WITH KELUN-BIOTECH IN ANTIBODY-DRUG CONJUGATE**

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 23 December 2022 (the “**Announcement**”) in relation to the collaboration between Nona Biosciences and Kelun-Biotech. Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcement.

As mentioned in the Announcement, under the Supplemental Agreements, Nona Biosciences is entitled to receive 30% of the proceeds derived from the two licensed ADC products (product 1 and product 2) jointly developed by Nona Biosciences and Kelun-Biotech to a licensed third party. The board of directors of the Company is pleased to announce the further information for product 1 and product 2 (subject to the exercise of the option) as follows:

Product 1

- Upfront payment: US\$30 million;
- Milestone payments: approximately US\$1,300 million in aggregate, including regulatory, development and sales milestones; and
- Royalty: tiered royalties of product 1.

Product 2

As informed by Kelun-Biotech, the licensed third party was granted an option to obtain an exclusive license to exploit product 2 under the Third Party Agreement, and the license to product 2 will only become effective once the said option is exercised by the licensed third party.

The Company will disclose further information in relation to product 2 when appropriate.

For the avoidance of doubt, Nona Biosciences is entitled to 30% of the above payments of product 1 and product 2 (if the option is exercised) under the Supplemental Agreements.

**Warning under Rule 18A.05 of the Listing Rules:** There is no assurance that any products as stated in this announcement will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

### **Forward-Looking Statements**

This announcement may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the Company, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this announcement; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.

By order of the Board  
**HBM Holdings Limited**  
**Dr. Jingsong Wang**  
*Chairman and Executive Director*

Hong Kong, 4 August 2023

*As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Mr. Ka Chi Yau and Dr. Albert R. Collinson as independent non-executive Directors.*